Abstract: Phosphatidylinositol (P1) 3-kinase is activated by a variety of agents, including various growth factors, and has been proposed to play a role in initiation of cell growth, proliferation, and differentiation. We here investigate the effect of various membrane lipids on P1 3-kinase immunopurified from human SH-SY5Y neuroblastoma cells. CDP-diacylglycerol (CDP-DAG) inhibited Fl 3-kinase activity with an lC~õf 6~tM. Phosphatidate (PA) was also inhibitory (1050 = 38 1iM) as was lysophosphatidate. Neither DAG nor any of the other phospholipids examined affected P1 3-kinase activity. The results offer the possibility that CDP-DAG or PA at critical membrane sites may exert functionally significant metabolic regulation at the point of convergence of the P1 3-kinase-directed and the P1 4-kinase-directed phosphoinositide signal transduction pathways. Key Words: Phosphatidylinositol 3-kinase-CDP-diacylglycerol-Lysophosphatidate-Phosphatidate-SH-SY5Y neuroblastoma cells. J. Neurochem. 66, 811-816 (1996).
The SH-SY5Y human neuroblastoma cell line (Pahlman et al., 1990) has proven useful for studying the ligand-stimulated receptor-mediated cleavage of phosphatidylinositol 4,5-bisphosphate [Ptdlns (4,5) P2 P1(4,5)P2] into the two chemical second messengers diacyiglycerol (DAG) and D-myo-inositol I ,4,5-trisphosphate [1(1,4,5 )P1] (Fisher et al., 1992) . This subclone is enriched in muscarinic cholinergic receptors and has served as a model system for studies on physiological regulation of the phosphoinositide signal transduction system and of intervention by neuropharmacological agents (Gray et al., 1994) . Resynthesis of PI(4,5)P2 proceeds via phosphorylation of DAG by DAG-kinase and conversion of the resulting phosphatidate (PtdOH; PA) to cytidine diphosphodiacylglycerol (CDP-DAG), which serves, in turn, together with mositol, as a cosubstrate of PT synthase. For the newly formed phosphatidylinositol (P1) to reenter the signal transduction pathway requires that it be phosphorylated sequentially, first at the 4' position of inositol, to form phosphatidylinositol 4-phosphate (PI4P), then at the 5' position to form Pl(4,5)P2. Over the past few years, an alternate fate of PT has been described in which P1 3-kinase acts on P1 to produce phosphatidylinositol 3-phosphate (PI3P) (Whitman et al., 1988; Carpenter and Cantley, 1990; Panayotou and Waterfleld, 1992; Parker and Waterfield, 1992; Carter and Downes, 1993; Stephens et al., 1993) . This isomeric phosphatidylinositol phosphate (PIP), as well as phosphatidylinositol 3,4-bisphosphate [P1(3,4) P2] and phosphatidylinositol 3,4,5-trisphosphate [P1(3,4,5 ) Pa], termed collectively the "3'-phosphoinositides," have been identified in various tissues and cultured cells in association with growth and differentiation, e.g., after the addition to media of various growth factors (Parker and Waterfield, 1992) . There is evidence that intact 3 '-phosphoinositides are chemical messengers (Nakanishi et al., 1993; Stephens et al., 1993; Toker et al., 1994) , although it remains possible that there are as yet unidentified cleavage products that mediate signal transduction via this pathway. Although it is likely that some 3-phosphoesterification occurs directly on PI4P and on PI(4,5)P2, the phosphorylation of P1 by either P1 3-or 4-kinase would appear to constitute a metabolic branch point, the regulation of which could affect either or both of the pathways. We have established the presence of P1 3-kinase activity in SH-SY5Y cells, as well as its modification by CDP-DAG and by PA, and raise the possibility that regulatory feedback occurs in inositol lipid-mediated signal transduction.
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EXPERIMENTAL PROCEDURES
Materials
ATP, phospholipids (unless otherwise specified), CMP, CDP, CTP, CDP-glycerol, and bovine serum albumin were purchased from Sigma Chemical (St. Louis, MO, U.S.A.). Stearoylarachidonoyl-CDP-DAG was a generous gift of A. K. Hajra. CDP-DAG (from egg lecithin) was from Serdary Research (London, Ontario, Canada). Cardiolipin was the product of Avanti Polar Lipids (Alabaster, AL, U.S.A.). iy-~2 P]ATP (3,000 Ci/rnmol) was from Du Pont-NEN (Wilmington, DE, U.S.A.). Silica gel 60 TLC plates were from Merck (Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and protein A-agarose were purchased from GibcoBRL (Gaithersburg, MD, U.S.A.). Anti-p85 antiserum was from Upstate Biotechnology Incorporated (Lake Placid, NY, U.S.A.). SH-SY5Y cells (60-80 passages) were grown to confluency and treated as described herein.
Preparation of P1 3-kinase
P1 3-kinase was prepared from confluent SH-SY5Y cells grown in DMEM supplemented with 10% FBS at 37CC in a humidified atmosphere of 10% CO 2. Cells, grown in 150-mm culture dishes, were washed twice with 15 ml of phosphate-buffered saline (PBS), pH 7.4, aspirated, and lysed with 2 mI/dish of lysis buffer containing 137 mM NaCI, 20 mM Tris-HCI (pH 8.0), 1 mM EDTA, 1 mM MgCI2, 1 mM CaCI2, 10% glycerol, 1% Nonidet P-40 (NP-40), 10 pg/mI leupeptin, 2 pg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate. The cells were scraped free from the dishes and centrifuged at 6,000 g for 10 mm. The resulting supernatant was incubated in 50-ml conical plastic tissue-culture tubes with shaking overnight with 4 pg of anti-p85 antiserum per milligram of protein, after which protein A-agarose beads were added for 2 h with mixing. Immune complexes bound to the beads were washed three times with PBS containing 1% NP-40, twice with PBS containing 0.5 M LiCI and 0.1 M Tris-HCI (pH 7.5), and twice with 0.1 M NaCI containing 1 mM EDTA and 10mM Tris-HCI (pH 7.5).
P1 3-kinase assay
The reaction mixture for measuring P1 3-kinase activity contained 50 p1 of the immunoprecipitated enzyme preparation (representing enzyme from 5 x 10~'cells) and 50 pl of P1 micelles that were prepared by sonicating 800 pg of P1 (Sigma, from bovine liver) in 1 ml of20 mM HEPES buffer (pH 7.6)containing I mMEDTA for 45 s (Kontes sonicator with a microtip probe). Fifty microliters of HEPES buffer or various sonicated lipids to be tested were added at this poinl. The mixture was preincubated for 15 mm at room temperature. and the reaction was started by addition of 50 p1 of 20 mM MgCI2 containing 150 pM [y-32P]ATP (20 pCi per assay). The reaction was terminated after 10 mm by the addition of 200 p,1 of 1 M methanolic HCI followed by 200 pl of chloroform. The resulting organic phase was dried, resuspended in 25 pl of chloroform/methanol (1: 1), and spotted on a TLC plate that was precoated with I % potassium oxalate. The plate was developed in chloroform! methanol/H 20/7.7 M ammonium hydroxide (60:47:11.3:2) (Serunian et al., 1991) . 32P-labeled PI3P was visualized by autoradiography and compared with an iodine-stained authentic PI4P standard. Radioactivity in PI3P was quantitated by liquid scintillation spectrometry.
FIG. 1.
Immunoblot and enzymatic activity of P1 3-kinase isolated from SH-SY5Y cells with p85 anti-sera. A: Fl 3-kinase was immunoprecipitated from SH-SY5Y cells, as described in Experimental Procedures, and immunoblotted after SDS-PAGE, using either preimmune rabbit anti-serum (Pre.l.) or anti-p85 anti-serum (a-p85). The prominent spots above the 45-kDa mark represent lgG. B: The immunoprecipitates were assayed for P1 3-kinase activity as described in the text. Lane 1, preimmuneserum immunoprecipitates; lane 2, ct-p85 immunoprecipitates; lane 3, cs-p85 + 0.5% NP-40; lane 4, a-p85 + 50 nM WT. The data shown are representative of three independent experiments, which gave similar results.
Immunoblotting of the p85 subunit of P1 3-kinase
Cells were lysed, followed by immunoprecipitation with anti-p85 antiserum as described. After washing, immune complexes were resolved on 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to nitrocellulose paper and analyzed for the presence of p85 by protein immunoblot using anti-p85 antiserum. Bound antibodies were visualized by an enhanced chemiluminescence (ECL) detection system, using horseradish peroxidase conjugated to anti-rabbit lgG as the secondary antibody (Amersham, Arlington. Heights, IL.
U.S.A.).
RESULTS
Assay of P1 3-kinase
Human SH-SY5Y neuroblastoma cells were found to be a ready source of P1 3-kinase. The presence of the p85 protein in anti-p85 immunoprecipitates from these cells was confirmed by western blotting with the same antiserum and detection by ECL (Fig. IA) . A major band at the 85-kDa region was visualized in the anti-p85 antiserum immunoprecipitates and not in those prepared with preimmune rabbit serum. PT is the .1. Neuroihi'ni., Vol. 66. No. 2, 1996 major intracellular substrate for P1 3-kinase (Berggren et al., 1993) and was thereft)re used for these studies.
Optimum incubation conditions were those described by Serunian et al. (1991) ; phosphorylation in SH-SY5Y cells was found to be linear with time and enzyme concentration (not shown). As indicated in Fig.  1B , P1 phosphorylation to PIP was detected in the antip85 immunoprecipitates but not in preimmune rabbit serum immunoprecipitates. To examine the possible presence of P1 4-kinase activity in the preparations, we performed the phosphorylation reaction in the presence of NP-40, a detergent known to inhibit P1 3-kinase activity and to stimulate P1 4-kinase activity (Carpenter and Cantley, 1990) . Addition of 0.5% NP-40 to the reaction mixture inhibited the formation of 32P-Iabeled lipid completely, indicating the absence of detectable P1 4-kinase activity in the preparation. Furthermore, we found that wortmannin (WT) inhibited the phosphorylation of P1 in our preparation completely (Fig. IB) . WT is found in a variety of fungi and has been shown to selectively block P1 3-kinase activity in vitro and in vivo by binding covalently to the I lO-kDa subunit of P1 3-kinase (Powis et al., 1994) .
Effect of various lipids on P1 3-kinase activity
Membrane-bound enzymes, especially those that mediate membrane lipid metabolism are generally known to be responsive to their lipid environment (Hjelmstad and Bell, 1991) . We therefore examined the effect of various membrane lipids on P1 3-kinase activity in vitro at saturating concentrations of Mg2~, ATP, and P1. As shown in Fig. 2 , egg phosphatidylcholine (PC)-derived CDP-DAG and stearoyl-arachidonoyl-CDP-DAG produced 93 and 88% inhibition of PI3P formation, respectively. The observed block by CDP-DAG, therefore, does not appear to be highly selective with regard to the fatty acid composition of the molecule. CDP-glycerol, the deacylated form of CDP-DAG, had no effect on P1 3-kinase activity (see Table I ), indicating that fatty acyl substituents are required for the inhibitory effect. Lyso-CDP-DAG was not tested. P1 3-kinase activity was also inhibited, albeit to a lesser extent (59%), by PA. l-Oleoyl-snglycero-3-P (lyso-PA; LPA) inhibited P1 3-kinase to the same extent as PA (t = 0.4, NS), whereas lyso-PC was ineffective. None of the other phospholipids examined, i.e., PC, phosphatidylethanolamine, phosphatidylserine, or cardiolipin, significantly affected P1 3-kinase activity, nor did either of two species of DAG used in this study, dioleoylglycerol or stearoylarachidonoyldiacylglycerol (also see Fig. 3B ).
Characterization of the inhibitory effect of CDP-DAG on P1 3-kinase
The concentration dependence of the inhibition of P1 3-kinase activity by CDP-DAG and PA is evident in an autoradiogram made after TLC separation of phosphorylated P1 lipids from P1 3-kinase assays, which contain the inhibitory lipids (Fig. 3A) . The plots in Fig. 3B demonstrate that CDP-DAG and PA inhibit P1 3-kinase in a dose-dependent manner, with estimated lC 5~values of 6 and 38 pM, respectively. Because of the unique structure of CDP-DAG, we investigated the possibility that separate nucleotideand lipid-binding sites, acting together, might explain the liponucleotide's blocking action. By adding various moieties of CDP-DAG alone or together, we established that the intact molecule is required for inhibition. Neither cytidine mono-, di-, nor triphosphate altered P1 3-kinase activity (Table 1) . Addition of PA and CMP together produced inhibition similar to that caused by PA alone, and the combination of DAG plus CDP had no effect, confirming that the inhibitory effect of CDP-DAG requires the intact liponucleotide molecule. To examine the nature of the inhibition further, we determined whether the effect of CDP-DAG could be reversed by the addition of various concentrations of the substrate P1 or ATP. As shown in Table 2 , even with concentrations of P1 and/or ATP five to 10 times higher than were routinely used, the degree of inhibition was unaffected. Although we did not examine these effects at other CDP-DAG concentrations, it does not appear likely that CDP-DAG is a competitive inhibitor with respect to P1 or ATP.
DISCUSSION
Demonstration of the presence of P1 3-kinase in SH-SYSY neuroblastoma cells and its inhibition by two endogenous classes of lipids was made possible by the availability of a high-affinity anti-p85 (regulatory subunit) antibody that permitted us to immunopurify an enzyme complex that also contained the 1 l0-kDa catalytic subunit of PT 3-kinase. The isolated protein complex phosphorylated P1 to a product that migrated on TLC to a region predicted for PIPs. Although PI3P and PI4P are not easily separable, the conclusion that the product was solely PI3P was also supported by the complete block of phosphorylation in the presence of WT, an agent known to block selectively P1 3-kinase but not P1 4-kinase. The result also indicated that there was no detectable activity for a recently described WTinsensitive P1-specific P1 kinase (Stephens et al.. 1994) in these cells.
Although the inhibitory effect of CDP-DAG does not appear to be restricted to a specific species of the liponucleotide, fatty acylation of the glycerol moiety is essential for the inhibitory action, as is the CDP head group, because CDP-glycerol and DAG are without effect, whereas inhibition, albeit to a lesser extent, is observed with PA. The block by PA is in agreement with a previous report (Carpenter et al., 1990) in which purified P1 3-kinase from rat liver was shown to be inhibited 50% by 10 p.M PA. LPA was equally effective, as has been observed with other cellular actions of PA and LPA such as their mitogenic actions (Moolenaar, 1995) . Recent studies indicate that LPA can activate PT 3-kinase (Kumagai et al.. 1993; Moolenaar, 1995) . The stimulatory effect is distinct from the present report of an inhibitory action of LPA in that the former is mediated by its receptor and a G proteinlinked signal transduction cascade, whereas the latter is the direct action of LPA on P1 3-kinase. Inhibition of P1 3-kinase by CDP-DAG has not been reported previously, although its block of P1 4-kinase has been observed in yeast, as discussed herein. Both CDP-DAG and PA are negatively charged phospholipids, and the mechanism of the observed inhibition might therefore be attributed to their negative charge. However, phosphatidylserine and cardiolipin, which are also negatively charged, had no effect on P1 3-kinase activity. Although it remains possible that a negative charge on inhibitory lipids is necessary, it does not appear to be P1 3-kinase activity in anti-PI 3-kinase antibody immunoprecipitates was assayed in the presence of the indicated concentratIons of P1, ATP, and 5t) pM CDP-DAG. The assay was started by adding the enzyme, allowing equal opportunity for the inhibitor and the competing substrates to bind. The determined lipid kinase activity is given as a percentage of the uninhibited (tiiinmts L'DP-DAG) lipid kinase activity (100~4)for each case. The 'esults represent mean ±SD values of duplicate determinations and ate typical of tht'ee experiments.
. 1. Neurorheni., Vol. 66, No. 2, 1996 CDP-DAG sufficient for the inhibitory effect. The loci of CDP-DAG and PA binding are unknown but do not appear to be at the ATP-or P1-binding sites. On the basis of findings in the analogous yeast protein VPS34, an inferred lipid-binding site should be considered (see Stephens et al., 1993) .
The relevance of these observations to in vivo conditions remains questionable. CDP-DAG is a quantitatively minor lipid; Thompson and Macdonald ( l976) reported the presence of 13.2 prnol CDP-DAG/kg of bovine brain. The present finding of an TCS() of 6 p.M for inhibition of PT 3-kinase suggests that CDP-DAG could well regulate this enzyme in vivo. Inhibition would be further enhanced under conditions in which intracellular CDP-DAG appears to be elevated. When tissue slices (Godfrey, 1989) or cultured cells (Stubbs and Agranoff, 1993) are pretreated with labeled cytidine, and then with carbachol in the presence or absence of Li~labeled CDP-DAG is greatly increased, presumably because PI-synthase activity has become substrate limited for free inositol, on the basis of the inhibition of inositol monophosphatase by Li + (Berridge et al., 1989) . In the case of SH-SY5Y cells, the increase is seen only if they have been deprived of inositol in the incubation medium as well (Stubbs and Agranoff, 1993) . Although CDP-DAG mass has not been measured in rat brain, I
3H ] cytidine-labeling studies in neurotransmitter-stimulated rat brain slices indicate a heterogeneous distribution that is presumed to indicate a broad range of amounts of the liponucleotide among brain cell types as well (Hwang et al., 1990) . It is of interest that the concentration of' CDP-DAG in plasma membranes of inositol-starved Inol yeast cells was found to be 12-fold higher than in inositolsupplemented cells, and that this elevation was associated with inhibition of P1 4-kinase (Nickels et al., 1994) . Tt is not yet known whether mammalian P1 4-kinase activity is affected by phospholipids. CDP-DAG in eukaryotic cells appears to be compartmented intracellulary in distinct mitochondrial and endoplasmic reticulum sites for the formation of cardiolipin and phospoinositides, respectively (Mok et a!., 1992) . On the basis of the recent cloning of a Drosophila CDP-DAG synthase (CDS) gene and identification of a defective mutant (Wu et al., 1995) , it appears that cell types may vary in isoforms of CDS and thus could also vary in levels of CDP-DAG under resting and stimulated conditions. Although PA inhibits P1 3-kinase with a somewhat higher IC 5~1(38 pM) than found for CDP-DAG, it should be noted that PA is present in 100-fold higher amounts than CDP-DAG in adult rat brain, and increases with age from 14 p.M in 3-day-old rats to 1.3-1.4mM in 330-day-old rat brains (Wells and Dittmer, 1967) . A similar value for PA was found in bovine brain (Thompson and Macdonald, 1976) . We have previously reported that SK-N-SH cells, the parent line of the SH-SY5Y subclonc, contain 20 nmol PA/mg of protein (Lee et al., 1991) , corresponding to a calculated concentration of 20 pM, and that carbachol more than doubles the PA concentration, bringing it well within the range of the in vitro IC50 (38 pM) observed in this study. In addition, hormoneinduced generation of PA is reported to occur widely via activation of phospholipase D or the sequential activation of phospholipase C and DAG kinase (see Liscovitch, 1992) . It may then be concluded that unless intracellular compartmentation prevents access, PA likely regulates P1 3-kinase in vivo.
These in vitro studies suggest that in vivo regulation of P1 3-kinase activity by intracellular PA and/or by CDP-DAG may underlie a functional relationship of these metabolic precursors with the PI3P and PI4P inositol lipids.
